KOREA UNITED PHARM, INC. AI Stock Analysis
Want to see KR:033270 full AI Analyst Report?
KOREA UNITED PHARM, INC. (033270) AI Stock Analysis
KOREA UNITED PHARM, INC.
(Korea Exchange:033270)
The score is supported primarily by strong financial health and attractive valuation, especially minimal leverage, solid profitability, and a low P/E ratio. Weak technical momentum and recent margin pressure temper the outlook.
KOREA UNITED PHARM, INC. (033270) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 247.27B
- Dividend Yield
- 3.91%
- Average Volume (3M)
- 32.28K
- Price to Earnings (P/E)
- 4.4
- Beta (1Y)
- 0.09
- Revenue Growth
- 0.85%
- EPS Growth
- 25.23%
- Country
- KR
- Employees
- 936
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
KOREA UNITED PHARM, INC. Business Overview & Revenue Model
Company Description
Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields...
KOREA UNITED PHARM, INC. Financial Statement Overview
Summary
Strong financial profile driven by an exceptionally low 3.0% debt-to-equity ratio, growing equity, solid profitability, and improving operating cash flow. Recent margin pressure and uneven free cash flow conversion limit the score.
Income Statement
82Very PositiveBalance Sheet
94Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 298.08B | 288.76B | 288.71B | 278.94B | 262.52B | 221.04B |
| Gross Profit | 175.93B | 175.41B | 163.97B | 158.98B | 145.29B | 122.66B |
| EBITDA | 65.18B | 60.47B | 57.84B | 70.78B | 62.05B | 46.90B |
| Net Income | 76.16B | 38.31B | 32.45B | 48.26B | 45.28B | 28.65B |
Balance Sheet | ||||||
| Total Assets | 570.76B | 519.49B | 473.93B | 468.86B | 417.89B | 380.03B |
| Cash, Cash Equivalents and Short-Term Investments | 178.56B | 157.07B | 132.32B | 151.05B | 142.63B | 123.20B |
| Total Debt | 14.86B | 14.02B | 15.65B | 40.34B | 30.30B | 32.99B |
| Total Liabilities | 73.13B | 64.82B | 67.72B | 90.18B | 80.03B | 79.32B |
| Stockholders Equity | 497.12B | 454.63B | 406.21B | 378.68B | 337.86B | 300.71B |
Cash Flow | ||||||
| Free Cash Flow | 41.32B | 27.70B | 5.57B | 19.34B | 39.57B | 31.30B |
| Operating Cash Flow | 83.93B | 51.14B | 26.79B | 50.65B | 63.78B | 44.09B |
| Investing Cash Flow | -60.40B | -41.07B | 11.70B | -56.41B | -87.90B | -17.70B |
| Financing Cash Flow | -4.62B | -3.63B | -29.46B | 2.55B | -10.59B | -8.20B |
KOREA UNITED PHARM, INC. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:033270, the sentiment is Negative. The current price of 15590.00 is below the 20-day moving average (MA) of 16425.00, below the 50-day MA of 17323.80, and below the 200-day MA of 18545.75, indicating a bearish trend. The MACD of -523.92 indicates Positive momentum. The RSI at 28.93 is Positive, neither overbought nor oversold. The STOCH value of 12.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:033270.
KOREA UNITED PHARM, INC. Peers Comparison
Overall Rating
KR:03327077Outperform
KR:09676072Outperform
KR:00312066Neutral
KR:00849062Neutral
KR:00929052Neutral
KR:00352040Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | KRW 226.20B | 4.36 | ― | 3.91% | 0.85% | 25.23% | |
| 72Outperform | KRW 256.35B | 3.04 | ― | 5.80% | 10.18% | 149.93% | |
| 66Neutral | KRW 93.64B | 36.24 | ― | 5.77% | -5.16% | -53.05% | |
| 62Neutral | KRW 178.68B | 4.87 | ― | 3.11% | 9.19% | -6.51% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | KRW 294.94B | 24.97 | ― | 1.59% | 5.20% | -65.65% | |
| 40Underperform | KRW 145.40B | -18.09 | ― | ― | 1.83% | -860.37% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:033270 | KOREA UNITED PHARM, INC. | 15590.00 | -3188.72 | -16.98% | |
| KR:003120 | ILSUNG IS CO., LTD. | 20800.00 | -943.36 | -4.34% | |
| KR:003520 | YUNGJIN PHARM. CO. LTD | 795.00 | -1187.00 | -59.89% | |
| KR:008490 | Suheung Co. Ltd. | 16070.00 | -6979.88 | -30.28% | |
| KR:009290 | Kwang Dong Pharmaceutical Co., Ltd. | 6270.00 | 428.01 | 7.33% | |
| KR:096760 | JW Holdings Corporation | 3705.00 | 421.16 | 12.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
